Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 1061 to 1070 of 1090 total matches.
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
is common and other allergic
reactions can occur.
DRUG INTERACTIONS — Coadministration of
antacids ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
Two Neuraminidase Inhibitors for Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • Oct 08, 1999 (Issue 1063)
, and it is excreted largely unchanged in urine. Interactions with other drugs have not been
reported with either drug ...
Zanamivir, a neuraminidase inhibitor taken by inhalation, has been approved by the FDA for treatment of influenza. Oseltamivir phosphate, an oral neuraminidase inhibitor, will probably be approved soon.
Amlodipine - A New Calcium-Channel Blocker
The Medical Letter on Drugs and Therapeutics • Oct 30, 1992 (Issue 882)
interactions with other drugs have not been reported to date.
DOSAGE — The starting dosage of amlodipine ...
Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension, chronic stable angina, and vasospastic (Prinzmetal's) angina.
Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate
The Medical Letter on Drugs and Therapeutics • Feb 04, 2013 (Issue 1409)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1409)
February 4, 2013 ...
The FDA has approved a once-daily, extended-release
oral suspension of methylphenidate (Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity
disorder (ADHD). It is the first liquid formulation of the
drug to be marketed for once-daily use. A short-acting
oral solution (Methylin, and generics) has been available
since 2003.
Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014 (Issue 1455)
receptor, blocking the interaction
Table 1. Some Drugs for Metastatic Melanoma
Drug Mechanism Indication1 ...
The FDA has approved pembrolizumab (Keytruda –
Merck), a human programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable or
metastatic melanoma that has progressed following
treatment with ipilimumab (Yervoy) and, if the patient
is BRAF V600 mutation positive, a BRAF inhibitor. It
is the fi rst PD-1 inhibitor to be marketed in the US.
Nivolumab, another PD-1 inhibitor, is available in
Japan. Pembrolizumab was previously known as
lambrolizumab.
Do NSAIDs Interfere with the Cardioprotective Effects of Aspirin?
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
drugs Motrin Interactions ...
Low-dose aspirin is widely used as an antiplatelet drug to reduce the risk of cardiovascular disease (Medical Letter 2000; 42:18). Recent reports suggest that the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (Motrin, and others) may decrease the efficacy of aspirin for this indication. The manufacturer of Tylenol is capitalizing on these reports by advertising that aspirin-taking patients who need pain relief should use acetaminophen instead of ibuprofen.
Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
levels of PD-L1
expression (PD-L1 expressed on ≥50% of tumor cells).
Table 1. Some Drugs for Metastatic ...
The FDA has approved the immune checkpoint inhibitor
pembrolizumab (Keytruda – Merck), a programmed
death receptor-1 (PD-1) inhibitor, for first-line treatment
of patients with metastatic non-small cell lung cancer
(NSCLC) that highly expresses programmed death-ligand
1 (PD-L1) and has no epidermal growth factor
receptor (EGFR) mutations or anaplastic lymphoma
kinase (ALK) translocations. About 25% of patients with
advanced NSCLC have tumors with high levels of PD-L1
expression (PD-L1 expressed on ≥50% of tumor cells).
Pembrolizumab was approved earlier for treatment...
Echinacea for Prevention and Treatment of Upper Respiratory Infections
The Medical Letter on Drugs and Therapeutics • Apr 01, 2002 (Issue 1127)
interactions between echinacea and other drugs have not
been reported. A study comparing 206 women who ...
Echinacea, a plant also called purple coneflower, is widely used as a dietary supplement for prevention and treatment of colds.
A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
been reported with these drugs, but causality has not
been established.
DRUG AND LABORATORY INTERACTIONS — Use ...
The FDA has approved Entadfi (Veru), a fixed-dose
combination of the 5α-reductase inhibitor
finasteride and the phosphodiesterase type 5 (PDE5)
inhibitor tadalafil, for initial treatment of benign
prostatic hyperplasia (BPH) in men with an enlarged
prostate; use of the drug is limited to 26 weeks.
Entadfi is the first 5α-reductase inhibitor/PDE5
inhibitor combination to become available in the
US. Finasteride (Proscar, and generics) and tadalafil
(Cialis, and generics) are also available separately.
Omeprazole
The Medical Letter on Drugs and Therapeutics • Mar 09, 1990 (Issue 813)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Omeprazole (Losec - Merck), a new drug that suppresses gastric acid secretion, has been approved by the US Food and Drug Administration for short-term (four to eight weeks) treatment of severe or refractory gastroesophageal reflux and for long-term treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis. Although widely used abroad for treatment of peptic ulcers, it has not been approved for that indication in the USA.